Recent Peer Reviewed Publications

• 1. Singh K
  2. Rubenstein K
  3. Callier V
  4. Shaw-Saliba K
  5. Rupert A
  6. Dewar R
  7. Laverdure S
  8. Highbarger H
  9. Lallemand P
  10. Huang ML
  11. Jerome KR
  12. Sampoleo R
  13. Mills MG
  14. Greninger AL
  15. Juneja K
  16. Porter D
  17. Benson CA
  18. Dempsey W
  19. El Sahly HM
  20. Focht C
  21. Jilg N
  22. Paules CI
  23. Rapaka RR
  24. Uyeki TM
  25. Lane HC
  26. Beigel J
  27. Dodd LE
  SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.; The Journal of infectious diseases. 2024 Apr 24.
• 1. Davis EC
  2. Monaco C
  3. Insel R
  4. Järvinen KM
  Gut microbiome in the first 1000 days and risk for childhood food allergy.; Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2024 Mar 15.
• 1. Li JZ
  2. Melberg M
  3. Kittilson A
  4. Abdel-Mohsen M
  5. Li Y
  6. Aga E
  7. Bosch RJ
  8. Wonderlich ER
  9. Kinslow J
  10. Giron LB
  11. Di Germanio C
  12. Pilkinton M
  13. MacLaren L
  14. Keefer M
  15. Fox L
  16. Barr L
  17. Acosta E
  18. Ananworanich J
  19. Coombs R
  20. Mellors J
  21. Deeks S
  22. Gandhi RT
  23. Busch M
  24. Landay A
  25. Macatangay B
  26. Smith DM
  Predictors of HIV rebound differ by timing of antiretroviral therapy initiation.; JCI insight; Vol 9(3). 2024 Feb 08.
• 1. Miner MD
  2. deCamp A
  3. Grunenberg N
  4. De Rosa SC
  5. Fiore-Gartland A
  6. Bar K
  7. Spearman P
  8. Allen M
  9. Yu PC
  10. Manso B
  11. Frahm N
  12. Kalams S
  13. Baden L
  14. Keefer MC
  15. Scott HM
  16. Novak R
  17. Van Tieu H
  18. Tomaras GD
  19. Kublin JG
  20. McElrath MJ
  21. Corey L
  22. Frank I
  Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial.; EBioMedicine; Vol 100, pp. 104987. 2024 Feb 01.
• 1. Luther VP
  2. Paras ML
  3. Schultz S
  4. Aziz M
  5. Balba G
  6. McCarty TP
  7. Razonable RR
  8. Reece R
  9. Shnekendorf R
  10. Sundareshan V
  11. Chirch LM
  High-Volume, High-Acuity, and High-Impact Learning: Tips and Tricks for Infectious Diseases Training Programs.; Open forum infectious diseases; Vol 11(3), pp. ofae016. 2024 Jan 08.
• 1. Rick AM
  2. Laurens MB
  3. Huang Y
  4. Yu C
  5. Martin TCS
  6. Rodriguez CA
  7. Rostad CA
  8. Maboa RM
  9. Baden LR
  10. El Sahly HM
  11. Grinsztejn B
  12. Gray GE
  13. Gay CL
  14. Gilbert PB
  15. Janes HE
  16. Kublin JG
  17. Huang Y
  18. Leav B
  19. Hirsch I
  20. Struyf F
  21. Dunkle LM
  22. Neuzil KM
  23. Corey L
  24. Goepfert PA
  25. Walsh SR
  26. Follmann D
  27. Kotloff KL
  Risk of COVID-19 after natural infection or vaccination.; EBioMedicine; Vol 96, pp. 104799. 2023 Sep 20.
• 1. Rouphael N
  2. Winokur P
  3. Keefer MC
  4. Traenkner J
  5. Drobeniuc A
  6. Doi Y
  7. Munsiff S
  8. Fowler VG
  9. Evans S
  10. Oler RE
  11. Tuyishimire B
  12. Lee M
  13. Ghazaryan V
  14. Chambers HF
  Daily fosfomycin versus levofloxacin for complicated urinary tract infections.; mBio. 2023 Sep 12.
• 1. Branche AR
  2. Rouphael NG
  3. Diemert DJ
  4. Falsey AR
  5. Losada C
  6. Baden LR
  7. Frey SE
  8. Whitaker JA
  9. Little SJ
  10. Anderson EJ
  11. Walter EB
  12. Novak RM
  13. Rupp R
  14. Jackson LA
  15. Babu TM
  16. Kottkamp AC
  17. Luetkemeyer AF
  18. Immergluck LC
  19. Presti RM
  20. Bäcker M
  21. Winokur PL
  22. Mahgoub SM
  23. Goepfert PA
  24. Fusco DN
  25. Malkin E
  26. Bethony JM
  27. Walsh EE
  28. Graciaa DS
  29. Samaha H
  30. Sherman AC
  31. Walsh SR
  32. Abate G
  33. Oikonomopoulou Z
  34. El Sahly HM
  35. Martin TCS
  36. Kamidani S
  37. Smith MJ
  38. Ladner BG
  39. Porterfield L
  40. Dunstan M
  41. Wald A
  42. Davis T
  43. Atmar RL
  44. Mulligan MJ
  45. Lyke KE
  46. Posavad CM
  47. Meagher MA
  48. Stephens DS
  49. Neuzil KM
  50. Abebe K
  51. Hill H
  52. Albert J
  53. Telu K
  54. Mu J
  55. Lewis TC
  56. Giebeig LA
  57. Eaton A
  58. Netzl A
  59. Wilks SH
  60. Türeli S
  61. Makhene M
  62. Crandon S
  63. Montefiori DC
  64. Makowski M
  65. Smith DJ
  66. Nayak SU
  67. Roberts PC
  68. Beigel JH
  Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.; Nature medicine. 2023 Aug 28.
• 1. Rouphael NG
  2. Branche AR
  3. Diemert DJ
  4. Falsey AR
  5. Losada C
  6. Baden LR
  7. Frey SE
  8. Whitaker JA
  9. Little SJ
  10. Kamidani S
  11. Walter EB
  12. Novak RM
  13. Rupp R
  14. Jackson LA
  15. Babu TM
  16. Kottkamp AC
  17. Luetkemeyer AF
  18. Immergluck LC
  19. Presti RM
  20. Bäcker M
  21. Winokur PL
  22. Mahgoub SM
  23. Goepfert PA
  24. Fusco DN
  25. Atmar RL
  26. Posavad CM
  27. Netzl A
  28. Smith DJ
  29. Telu K
  30. Mu J
  31. McQuarrie LJ
  32. Makowski M
  33. Makhene MK
  34. Crandon S
  35. Montefiori DC
  36. Roberts PC
  37. Beigel JH
  Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.; The Journal of infectious diseases. 2023 Aug 10.
• 1. de Bruyn G
  2. Wang J
  3. Purvis A
  4. Ruiz MS
  5. Adhikarla H
  6. Alvi S
  7. Bonaparte MI
  8. Brune D
  9. Bueso A
  10. Canter RM
  11. Ceregido MA
  12. Deshmukh S
  13. Diemert D
  14. Finn A
  15. Forrat R
  16. Fu B
  17. Gallais J
  18. Griffin P
  19. Grillet MH
  20. Haney O
  21. Henderson JA
  22. Koutsoukos M
  23. Launay O
  24. Torres FM
  25. Masotti R
  26. Michael NL
  27. Park J
  28. Rivera-Medina DM
  29. Romanyak N
  30. Rook C
  31. Schuerman L
  32. Sher LD
  33. Tavares-Da-Silva F
  34. Whittington A
  35. Chicz RM
  36. Gurunathan S
  37. Savarino S
  38. Sridhar S
  Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.; EClinicalMedicine; Vol 62, pp. 102109. 2023 Jul 22.
• 1. Falsey AR
  2. Walsh EE
  Respiratory syncytial virus Prefusion F vaccine.; Cell; Vol 186(15), pp. 3137-3137.e1. 2023 Jul 20.
• 1. Lyke KE
  2. Atmar RL
  3. Dominguez Islas C
  4. Posavad CM
  5. Deming ME
  6. Branche AR
  7. Johnston C
  8. El Sahly HM
  9. Edupuganti S
  10. Mulligan MJ
  11. Jackson LA
  12. Rupp RE
  13. Rostad CA
  14. Coler RN
  15. Bäcker M
  16. Kottkamp AC
  17. Babu TM
  18. Dobrzynski D
  19. Martin JM
  20. Brady RC
  21. Frenck RW
  22. Rajakumar K
  23. Kotloff K
  24. Rouphael N
  25. Szydlo D
  26. PaulChoudhury R
  27. Archer JI
  28. Crandon S
  29. Ingersoll B
  30. Eaton A
  31. Brown ER
  32. McElrath MJ
  33. Neuzil KM
  34. Stephens DS
  35. Post DJ
  36. Lin BC
  37. Serebryannyy L
  38. Beigel JH
  39. Montefiori DC
  40. Roberts PC
  Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.; NPJ vaccines; Vol 8(1), pp. 98. 2023 Jul 11.
• 1. Theodore DA
  2. Branche AR
  3. Zhang L
  4. Graciaa DS
  5. Choudhary M
  6. Hatlen TJ
  7. Osman R
  8. Babu TM
  9. Robinson ST
  10. Gilbert PB
  11. Follmann D
  12. Janes H
  13. Kublin JG
  14. Baden LR
  15. Goepfert P
  16. Gray GE
  17. Grinsztejn B
  18. Kotloff KL
  19. Gay CL
  20. Leav B
  21. Miller J
  22. Hirsch I
  23. Sadoff J
  24. Dunkle LM
  25. Neuzil KM
  26. Corey L
  27. Falsey AR
  28. El Sahly HM
  29. Sobieszczyk ME
  30. Huang Y
  Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.; JAMA network open; Vol 6(7), pp. e2323349. 2023 Jul 03.
• 1. Falsey AR
  2. Branche AR
  3. Croft DP
  4. Formica MA
  5. Peasley MR
  6. Walsh EE
  Real-Life Assessment of BioFire FilmArray® Pneumonia Panel in Adults Hospitalized with Respiratory Illness.; The Journal of infectious diseases. 2023 Jun 27.
• 1. Rouphael NG
  2. Branche AR
  3. Diemert DJ
  4. Falsey AR
  5. Losada C
  6. Baden LR
  7. Frey SE
  8. Whitaker JA
  9. Little SJ
  10. Kamidani S
  11. Walter EB
  12. Novak RM
  13. Rupp R
  14. Jackson LA
  15. Babu TM
  16. Kottkamp AC
  17. Luetkemeyer AF
  18. Immergluck LC
  19. Presti RM
  20. Bäcker M
  21. Winokur PL
  22. Mahgoub SM
  23. Goepfert PA
  24. Fusco DN
  25. Atmar RL
  26. Posavad CM
  27. Netzl A
  28. Smith DJ
  29. Telu K
  30. Mu J
  31. Makowski M
  32. Makhene MK
  33. Crandon S
  34. Montefiori DC
  35. Roberts PC
  36. Beigel JH
  Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.; medRxiv : the preprint server for health sciences. 2023 Jun 10.